These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 22902096)

  • 1. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statin and fibrate combination does not additionally lower plasma cholesteryl ester transfer in type 2 diabetes mellitus.
    de Vries R; Dikkeschei BD; Sluiter WJ; Dallinga-Thie GM; van Tol A; Dullaart RP
    Clin Lab; 2012; 58(11-12):1231-9. PubMed ID: 23289194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes.
    Triolo M; Annema W; de Boer JF; Tietge UJ; Dullaart RP
    Eur J Clin Invest; 2014; 44(3):240-8. PubMed ID: 24325778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
    Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS
    Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
    Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
    J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma apolipoprotein M responses to statin and fibrate administration in type 2 diabetes mellitus.
    Kappelle PJ; Ahnström J; Dikkeschei BD; de Vries R; Sluiter WJ; Wolffenbuttel BH; van Tol A; Nielsen LB; Dahlbäck B; Dullaart RP
    Atherosclerosis; 2010 Nov; 213(1):247-50. PubMed ID: 20828695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Lp-PLA(2) mass and apoB-lipoproteins that carry Lp-PLA(2) decrease after sodium.
    Constantinides A; Kerstens MN; Dikkeschei BD; van Pelt LJ; Tellis CC; Tselepis AD; Dullaart RP
    Eur J Clin Invest; 2012 Nov; 42(11):1235-43. PubMed ID: 22957745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of combined treatment with L-carnitine and simvastatin in lowering lipoprotein(a) serum levels in patients with type 2 diabetes mellitus.
    Solfrizzi V; Capurso C; Colacicco AM; D'Introno A; Fontana C; Capurso SA; Torres F; Gadaleta AM; Koverech A; Capurso A; Panza F
    Atherosclerosis; 2006 Oct; 188(2):455-61. PubMed ID: 16384561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
    J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
    Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes.
    Noto H; Chitkara P; Raskin P
    J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
    Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
    Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
    Miller M; Dobs A; Yuan Z; Battisti WP; Borisute H; Palmisano J
    Curr Med Res Opin; 2004 Jul; 20(7):1087-94. PubMed ID: 15265253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study.
    Miller M; Dobs A; Yuan Z; Battisti WP; Palmisano J
    Curr Med Res Opin; 2006 Feb; 22(2):343-50. PubMed ID: 16466606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.
    Iwase M; Sonoki K; Sasaki N; Ohdo S; Higuchi S; Hattori H; Iida M
    Atherosclerosis; 2008 Feb; 196(2):931-6. PubMed ID: 17350631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
    Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile.
    Dullaart RP; Constantinides A; Perton FG; van Leeuwen JJ; van Pelt JL; de Vries R; van Tol A
    J Clin Endocrinol Metab; 2011 Apr; 96(4):1077-84. PubMed ID: 21252249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
    QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.